Live Breaking News & Updates on கெல்லி ஓவந் தோப்பு
Stay updated with breaking news from கெல்லி ஓவந் தோப்பு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Taconic Biosciences Launches New COVID-19 Mouse Model Expands COVID-19 Research Toolkit with novel hACE2 AC22 Mouse RENSSELAER, N.Y., April 29, 2021 (GLOBE NEWSWIRE) Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces the launch of a new COVID-19 mouse model. This human ACE2 (hACE2) transgenic mouse expands Taconic’s COVID-19 research toolkit. In October 2020, Taconic launched its first hACE2 model. The AC70 mouse experiences a lethal response to infection by SARS-CoV-2, the virus that causes COVID-19. Conversely, the new AC22 mouse is lethality-resistant, enabling therapeutic, vaccine, and post-infection symptom research. Although various hACE2 mouse models of lethal SARS-CoV-2 infection exist, the hACE2 AC22 lethality-resistant model is important because it permits study of sublethal infection. Most humans infected with SARS-CoV-2 survive, and an animal model which replicates sublethal disease and recovery is ....
Taconic Biosciences Expands Scientific Advisory Board Dr. Monica Gostissa Joins Taconic Biosciences’ Scientific Advisory Board RENSSELAER, N.Y., March 15, 2021 (GLOBE NEWSWIRE) Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces Monica Gostissa, PhD, has joined its Scientific Advisory Board (SAB). Dr. Gostissa joins existing board members, Frank Sistare, PhD; Andrew Goodman, PhD; David Hill, PhD; and Robert Rosenthal, PhD. The SAB collaborates with Taconic management, providing scientific insight and guidance to expand the company’s product and service portfolio. Dr. Gostissa’s extensive career in the immunology and immuno-oncology fields brings new expertise to the board and complements Taconic’s leadership in these research areas. ....
Dr. Monica Gostissa Joins Taconic Biosciences’ Scientific Advisory Board RENSSELAER, N.Y., March 15, 2021 (GLOBE NEWSWIRE) Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces Monica Gostissa, PhD, has joined its Scientific Advisory Board (SAB). Dr. Gostissa joins existing board members, Frank Sistare, PhD; Andrew Goodman, PhD; David Hill, PhD; and Robert Rosenthal, PhD. The SAB collaborates with Taconic management, providing scientific insight and guidance to expand the company’s product and service portfolio. Dr. Gostissa s extensive career in the immunology and immuno-oncology fields brings new expertise to the board and complements Taconic’s leadership in these research areas. ....
Taconic Biosciences Expands Immuno-oncology Animal Model Portfolio Critical Jh Syngeneic Tumor Model Host Now Available on a B6 Background RENSSELAER, N.Y., Jan. 18, 2021 (GLOBE NEWSWIRE) Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces an expansion of its immuno-oncology portfolio. Immuno-oncology is a leading research priority because it uses the body s own immune system to effectively treat some types of cancer. Syngeneic tumor animal models play a critical role because they use standard inbred mice that have a competent immune system, which is required to evaluate immune-modulating therapies. These models are engrafted with mouse tumors derived from the same strain background; this genetic similarity between tumor and host prevents the host from rejecting the tumor. ....